Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Hepatobiliary disorders – page 6

  • 357 clinical trials
  • 141 recruiting
  • 239 conditions
  • 26 countries

Conditions in this area

239 conditions with trials, the busiest first

Hepatocellular carcinoma89Cholangiocarcinoma38Hepatic cirrhosis25Metabolic dysfunction-associated steatohepatitis22Colorectal cancer20Non-alcoholic steatohepatitis17Chronic hepatitis B16Hepatitis D14Primary biliary cholangitis14Cholangitis sclerosing12Endometrial cancer12Non-small cell lung cancer12Alpha-1 antitrypsin deficiency11Gastric cancer11Malignant melanoma11Biliary neoplasm10Hepatitis B10Breast cancer9Ovarian cancer9Bile duct cancer8Gallbladder cancer8Hepatic cancer8Pancreatic carcinoma8Adenocarcinoma pancreas7+215

Clinical trials in Hepatobiliary disorders

357 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

357 clinical trials

Glucose tolerance impaired+1

Recruiting

Study of Pioglitazone and Metformin combination treatment for patients with Metabolic Associated Fatty Liver Disease and prediabetes

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pioglitazone
  • Sponsor:Consorcio Centro De Investigacion Biomedica En Red

Endometrial cancer+18

Recruiting

Study on the Effectiveness and Safety of BAY 2927088 for Patients with Advanced Solid Tumors with HER2 Mutations

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Bay 2927088
  • Sponsor:Bayer AG

Cholangiocarcinoma

Recruiting

Study of Gemcitabine and Oxaliplatin Infusion for Patients with Non-Metastatic Unresectable Intra-Hepatic Cholangiocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Oxaliplatin
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Hepatocellular carcinoma

Recruiting

Study of DNAJB1-PRKACA Peptide Vaccine for Patients with Fibrolamellar Hepatocellular Carcinoma and Other Tumors with Oncogenic Driver Fusion

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Alpha-1 antitrypsin deficiency

Recruiting

Study on the Safety of Self-Infusion Therapy with Human Alpha1-Proteinase Inhibitor for Patients with Severe Alpha-1 Antitrypsin Deficiency

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human Alpha1-Proteinase Inhibitor
  • Sponsor:Grifols S.A.

Hepatic cirrhosis+1

Recruiting

Study Comparing Norfloxacin and Conventional Antibiotics for Hospitalized Patients with Decompensated Cirrhosis and Bacterial Infections

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Norfloxacin
  • Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’investigacions Biomediques August Pi I Sunyer

Portal hypertension+1

Recruiting

Study on Telmisartan for Reducing Portal Hypertension in Patients with Advanced Chronic Liver Disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Telmisartan
  • Sponsor:Medical University Of Vienna

Biliary cancer metastatic

Recruiting

Study Comparing Ivonescimab to FOLFOX Drug Combination for Patients with Advanced Biliary Tract Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Unicancer

Hepatic fibrosis

Recruiting

Study on the Effects of a Mediterranean Diet with Intermittent Fasting vs. Bupropion and Naltrexone in Overweight Patients with Type 2 Diabetes and Liver Fibrosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bupropion Hydrochloride
  • Sponsor:Sint Franciscus Vlietland Groep Stichting

Hepatic fibrosis+2

Recruiting

Study on Simvastatin for Reducing Liver Fibrosis in Patients with Advanced Alcohol-Related Liver Disease

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Simvastatin
  • Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’investigacions Biomediques August Pi I Sunyer

Hepatic cirrhosis+1

Recruiting

Study on Norfloxacin for Reducing Portal Hypertension in Patients with Decompensated Cirrhosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Norfloxacin
  • Sponsor:Medical University Of Vienna

Endometrial cancer+13

Recruiting

Study on Ifinatamab Deruxtecan for Patients with Recurrent or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ifinatamab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Substances studied in this area

The therapies tested most often in Hepatobiliary disorders trials.

Durvalumab37 clinical trialsBevacizumab29 clinical trialsAtezolizumab27 clinical trialsCisplatin26 clinical trialsLenvatinib22 clinical trialsTremelimumab22 clinical trialsGemcitabine20 clinical trialsInfliximab15 clinical trialsMycophenolate Mofetil15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.